Close 10 Sep 1505 scanned A
NIFTY 5023,477.80+0.20%
BANK NIFTY56,471.95+0.31%
INDIA VIX11.80-1.05%
MIDCAP 15022,904.25-0.38%
SMALLCAP 25018,433.40+0.01%
NEXT 5072,530.90-0.44%
BREADTH61%above 200-DMA
ADV / DEC558 / 939
NSE close 10 Sep

COHANCE

Cohance Lifesciences Limited
HealthcareMid capRs 17,037 crRs 40.8 cr traded a dayMultinationals
Close on 10 September 2026
445.30
+0.44%
52-week range26% of the way up
279.90904.75
Market cap
17,037 cr
P/E (TTM)
291.1×
industry 45×
EPS (TTM)
1.53
Revenue YoY
-23.1%
Q1 FY27
Profit YoY
-197.4%
Net margin
-10.7%
-19.1pt vs a year ago
Growth trend
-77.1pt
vs last quarter’s YoY
1 month
+0.2%
Below 52w high
103.2%
RSI (14)
40
Daily swing
3.3%
average true range
Volume
1.0×
vs 20-day average
Traded
Rs 41 cr
median day
Close200-day averageMaterial filing
2505007501,000Sep 25Nov 25Jan 26Mar 26May 26Jul 26Sep 26
260 sessions · hover for the filing behind a move

Key metrics

each ranked against every stock scanned tonight
Above the 200-day average
Around the median
+7.2%
One-year return
Bottom of the universe
-50.6%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
3 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
-23.1%
Below the 52-week high
from the highest close of the year
-50.8%
1 week
−3.37%
1 month
+0.21%
3 months
+4.29%
6 months
+45.40%
1 year
−50.61%

The read

written from the numbers on this page
The evidence leans negative3 supporting, 5 against, 0 worth knowing

Supporting

  • trading 7% above its 200-day average
  • matches beating the market for 6 months, which has beaten the market by +0.50 points over 20 sessions across 60,366 past signals
  • 4 independent kinds of evidence agree today, which is uncommon

Against

  • down 51% over twelve months
  • 2 of the scans it matches have historically underperformed the market
  • revenue fell 23% year on year in the quarter ending 30 June 2026
  • net margin has narrowed from 11.9% to -10.7% across four quarters
  • priced at 291× earnings against an industry median of 45× — 551% above its peers

Worth knowing

  • nothing the data supports either way
COHANCE sits in Multinationals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 415, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

from the filings and from the price, with the figure behind every line
Working2

Trading 7.2% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.

+7.2%

3 different kinds of evidence point at it tonight, not 3 versions of the same one.

3 families
Needs watching5

Net profit -197.4% year on year, Rs 46 cr to Rs -45 cr.

-197.4%Rs 46 crRs -45 cr

Profit growth was -197.4%, while revenue growth was -23.1%, showing profit grew slower than revenue.

-197.4%-23.1%

Net margin moved from 8.4% to -10.7%.

8.4%-10.7%

51% below its 52-week high.

-51%

Down 50.6% over the past year.

-50.6%
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 2 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.

How it has performed

price return over each window, beside the median NSE stock over the same days
this stockmedian NSE stock, same window-3.4%-2.6 pt vs market1W+0.2%+1.3 pt vs market1M+4.3%+1.6 pt vs market3M+45.4%+28.8 pt vs market6M-50.6%-47.4 pt vs market1Y

What the scans say today

4 of 47 matched on 10 Sep
COHANCE matches 4 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Valuation against its own history

500 sessions since 23 September 2024
63×
median 139×
288×
now 291×
COHANCE trades at 291× trailing earnings, above its median of 139× over this window — 109% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
08-27
17:22
Other filing
1 day-1.05 days+2.120 days
08-27
16:08
Other filing
1 day-1.05 days+2.120 days
08-26
20:15
Other filing
1 day-1.55 days+0.420 days
08-26
20:12
Other filing
1 day-1.55 days+0.420 days
08-26
19:44
AGM / EGM
1 day-1.55 days+0.420 days
08-13
12:35
Credit rating
1 day-0.05 days+1.620 days+0.8
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Credit rating filings were typically +0.38pt vs the market over the next 5 sessions (n=422)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
25830740254955654561942231.8%-10.7%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • nothing clear in the filed numbers

Going against it

  • revenue fell 23% against the same quarter a year earlier
  • profit dropped 197% year on year
  • net margin narrowed from 1.3% to -10.7%
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
30 Jun · consolidated
422-43-45-10.7%
Q4 FY26
31 Mar · consolidated
6192080.511.3%
Q3 FY26
31 Dec · consolidated
54541290.965.3%
Q2 FY26
30 Sep · consolidated
55684661.9411.9%
Q1 FY26
30 Jun · consolidated
54963461.288.4%
Q4 FY25
31 Mar · consolidated
40252391.659.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+0.2%
Versus 200-day average+7.2%
Below 52-week high-50.8%
Above 52-week low+59.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)39.6
Higher closes in last 52 of 5
Six-month return+45.40%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.27%
Volume versus 20-day1.0x
Median daily turnoverRs 40.8 cr

Peers

Healthcare · 68 classified companies
COHANCE trades at 291.1× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 551%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA446,51037.5−4.27%+13.20%260.5
DIVISLAB250,12085.5+9.75%+54.92%372.1
TORNTPHARM166,86180.7+0.76%+34.85%128.2
APOLLOHOSP127,98258.9+3.52%+15.00%261.1
ZYDUSLIFE111,55625.5−7.24%+7.93%133.6
CIPLA110,94233.1−6.13%−10.95%108.3
LAURUSLABS105,07996.4+5.14%+115.20%353.0
MAXHEALTH101,08169.4+3.09%−11.35%184.0
AUROPHARMA96,00025.9+0.08%+49.31%122.2
DRREDDY95,44030.0−4.75%−12.17%122.9
LUPIN95,00717.1−8.91%+3.66%155.0
COHANCE17,037291.1+0.21%−50.61%40.8
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
10 Sep1Profit falling while the price holds up
9 Sep1Profit falling while the price holds up
8 Sep1Profit falling while the price holds up
7 Sep1Profit falling while the price holds up
4 Sep1Profit falling while the price holds up
3 Sep1Profit falling while the price holds up
2 Sep1Profit falling while the price holds up
1 Sep1Profit falling while the price holds up
31 Aug1Profit falling while the price holds up
28 Aug1Profit falling while the price holds up
27 Aug1Profit falling while the price holds up
26 Aug1Profit falling while the price holds up